Blog

Tuberculosis (TB) is the leading cause of death from an infectious disease. Although a quarter of the world’s population is thought to carry latent TB, it carries a risk of progressing to the active form of TB in around 10%...

Tuberculosis (TB) is the leading cause of death from an infectious disease. Although a quarter of the world’s population is thought to carry latent TB, it only progresses to active disease in around 10% of those infected. The reasons for...

After growing PBD Biotech from start-up to international player in just three years, Dr Berwyn Clarke has decided to retire as CEO to make time for other business interests. He will remain on the diagnostics company’s Board of Directors.

A new blood test for tuberculosis (TB) could, for the first time, enable screening of patients at an early stage of infection.

PBD Biotech Limited is pleased to announce that its key technology patent has been granted by the European Patent Office.

Following PBD Biotech’s successful seed funding round, CEO Dr Berwyn Clarke spoke to Growth Business, the leading media portal for entrepreneurs, about the start-up’s strategic approach to securing the right investment for phage-based technology.

PBD Biotech Ltd is delighted to announce that it has successfully completed an over-subscribed seed investment round composed of angel investment from Cambridge Agritech Ltd and Anglia Capital Group.

Reported by Dr Catherine Rees at Viruses of Microbes 2016 Conference.

A research paper has been published in Virulence journal, by Benjamin Swift, Thomas Convery and Catherine Rees: 'Evidence of Mycobacterium tuberculosis complex bacteraemia in intradermal skin test positive cattle detected using phage-RPA'.